Can you generate antibodies against challenging membrane proteins?

Yes. We have experience generating antibodies against challenging targets, including GPCR antibody services.

Do you use human naïve antibody libraries?

Yes. We work with fully human antibody libraries for antibody discovery.

Do you also work with immune libraries?

Yes. We also work with immune libraries when they are the most relevant approach for the project.

Can you prioritize binders that recognize native antigen conformation on cells?

Yes. We can design the screening strategy to prioritize binders that recognize the native conformation of the antigen on the cell surface.

Can you convert antibodies into scFv formats suitable for CAR constructs?

We can generate scFv directly through our phage display platform, making them well suited for CAR construct development.

Can you help reduce potential scFv aggregation or instability?

Yes. Through our AI-driven antibody developability assessment service, we can help identify and address liabilities related to aggregation, instability, or poor biophysical behavior.

Can you humanize an antibody while preserving its binding properties?

Yes. We offer antibody humanization services designed to reduce immunogenicity risk while preserving the original antibody’s binding profile, specificity, and functional relevance as much as possible. AI-driven antibody humanization service

Can we define the selection criteria together before starting the project?

Yes. We work closely with you upfront to define the most relevant selection criteria based on your target, application, and development goals.

Can the screening strategy be adjusted based on intermediate results?

Yes. Our projects are designed with go/no-go decision points, and the screening strategy can be adjusted along the way based on intermediate findings.

Custom CAR-T cell development service

Turn your candidate into a high-potential CAR lead

0x10¹⁰

human antibody clones for CAR design

Up to 0

binder sequences delivered

0 weeks

from antigen design to CAR construction

Get up to 10 binder sequences to advance your CAR-T project toward the clinic

Our flexible workflow adapts to your timeline and budget constraints, helping advance your CAR-T program toward the clinic through tailored custom antibody services. You receive up to 10 binder sequences with full IP ownership, aligned with your project requirements, along with a detailed results report offering clear, actionable insights to support decision-making. Dedicated support for CAR construct design helps turn selected binders into promising CAR-T candidates for downstream development.

Contact our team to explore the best approach for your project

Case report

Discover how ProteoGenix identified 36 positive hits against a novel peptide-HLA target and delivered 3 TCR-like antibody sequences for CAR-T validation

Case Report: TCR-like antibody development against a novel peptide-HLA complex for cancer immunotherapy

See the results here

Start with fully human antibody for challenging targets to reduce development risk

Our scFv discovery service helps you identify relevant CAR binders against challenging targets. You start from a fully human library, which removes the need for additional humanization and reduces development risk. It supports a smoother path toward clinical development.

Access broad sequence diversity to improve your chances of success

You benefit from a naïve cancer antibody library built from patients with 18 different types of cancer. This supports broad repertoire diversity for candidate discovery. The library includes more than 6 × 10¹⁰ scFv and Fab clones. A sequence in-frame frequency above 95% supports the identification of high-quality candidates.

Screen scFv binders directly on cells for more relevant CAR binder selection

Up to 6 rounds of cell-based library panning are performed directly on cells. This approach helps identify scFv binders that recognize the native form of the antigen on the cell surface. It helps you focus on more relevant and functional candidates.

Discuss your CAR binder discovery strategy with our experts

Video from our experts

How we turned complexity into a GPCR-Targeting CAR-T strategy

Karim Sebane, Business Manager for Monoclonal Antibodies at ProteoGenix, shares the key steps behind a complex CAR-T project, highlighting what made this ambitious program a success.

One expert partner to simplify your CAR-T project from antigen design to delivery in 10 weeks

Benefit from integrated therapeutic antibody services designed to simplify your CAR-T project from antigen design stage. Combining scientific expertise with high-quality execution, each step helps you generate and advance the most promising candidates for your CAR-T program within 10 weeks.

End-to-end workflow

Antigen design services

Selection of the most relevant CAR-T cell therapy target
Design of the appropriate antigen and production

Monoclonal antibody discovery services

Selection of the most suitable workflow based on your target, timeline, and development goals: hybridoma sequencing service, single B-cell antibody service, or phage display service
Generation and screening of lead candidates for CAR-T applications
Optional antibody optimization: AI-driven affinity maturation platform